Gleevec/Glivec

New drugs can't keep Novartis sales on the up

compensate for a $290m reduction in sales of cancer drug Glivec (imatinib) to $544m, with overall group sales down 1% to $11.53bn.

Novartis 'reviewing options' for Alcon division

year. The company is expecting 2017 to continue to be pressured as former top-selling cancer drug Glivec/Gleevec (imatinib) continues to face generic competition, with a return to growth next

Takeda agrees $5.2bn deal to buy Ariad

The multi-targeted tyrosine-kinase inhibitor drug is facing stiff competition from other drugs in the class including Novartis' Glivec/Gleevec (imatinib) and generic equivalents in some markets.

NICE backs BMS leukaemia drug Sprycel

to 66% of patients taking Novartis' Gleevec (imatinib), the current standard care. ... With a list price of £30, 000 per patient per year, Sprycel was originally rejected due to its lack of cost-effectiveness, and NICE approved the cheaper Gleevec.

Novartis says its biosimilar sales should reach $1bn this year

The biosimilar franchise helped Novartis shrug off a second quarter of generic competition for its cancer drug Gleevec in the US, a lacklustre performance from its Alcon eyecare division and less

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]